Impax Laboratories (IPXL) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Impax Laboratories (IPXL) PT Lowered to $16 at Cowen
November 10, 2017 8:15 AM ESTCowen lowered its price target on Impax Laboratories (NASDAQ: IPXL) to $16.00 (from $17.00) while maintaining a Market Perform rating. The Concerta delay and Renvela update were disappointing, but management is able to accelerate the previously announced cost reductions to partially offset this lack of... More
Impax Laboratories (IPXL) PT Raised to $35 at Cantor Fitzgerald
November 9, 2017 11:44 AM ESTCantor Fitzgerald raised its price target on Impax Laboratories (NASDAQ: IPXL) to $35.00 (from $25.00) while maintaining a Overweight rating following mixed Q3 results.
Analyst Louise Chen said the increase in the price target is a result of upward earnings revisions in 2019+. This... More
